The potential impact of expanding target age groups for polio immunization campaigns

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Duintjer Tebbens, Radboud J ^a   Kalkowska, Dominika A ^a,b   Wassilak, Steven G F ^c   Pallansch, Mark A ^d   Cochi, Stephen L ^c   Thompson, Kimberly M ^a,e  

^a Kid Risk Inc   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Disease outbreaks; Dynamic modeling; Eradication; Polio

Indexed keywords

POLIOMYELITIS VACCINE;

ADOLESCENT; ADULT; CHILD; EPIDEMIC; HUMAN; IMMUNOLOGY; INDIA; INFANT; NIGERIA; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; TAJIKISTAN; THEORETICAL MODEL; TRANSMISSION; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; HUMANS; INDIA; INFANT; MODELS, THEORETICAL; NIGERIA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; TAJIKISTAN; VACCINATION;

EID: 84893807698     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-45     Document Type: Article

References (45)

1. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine -- live. Vaccines. Fifth edition 2008, Philadelphia: Saunders Elsevier, Plotkin SA, Orenstein WA, Offit PA.
2. World Health Organization Transmission of wild poliovirus type 2 - apparent global interruption. Wkly Epidemiol Rec 2001, 76:95-97. World Health Organization.
3. Global Polio Eradication Initiative - list of wild poliovirus by country. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Wildpolioviruslist.aspx.
4. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013, 33:647-663. 10.1111/j.1539-6924.2012.01891.x, 22985171.
5. World Health Assembly Poliomyelitis: intensification of the global eradication initiative (resolution 65.5) 2012, Geneva, Switzerland: World Health Organization, World Health Assembly.
6. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013, 33:516-543. 10.1111/risa.12019, 23461599.
7. Hull HF, Ward NA, Hull BP, Milstien J, de Quadros CA. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 1994, 343:1331-1337. 10.1016/S0140-6736(94)92472-4, 7910329.
8. World Health Organization Global polio eradication initiative: polio eradication and endgame strategic plan (2013-2018). 2013, Geneva, Switzerland: World Health Organization, Report No.: WHO/POLIO/13.02, World Health Organization.
9. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, Spigland I, Koch MA, Barnes JM JSR. Live, orally given poliovirus vaccine: effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960, 173:1521-1526. 10.1001/jama.1960.03020320001001, 14440553.
10. Olive JM, Risi JB, de Quadros CA. National immunization days: experience in Latin America. J Infect Dis 1997, 175(1):S189-S193.
11. Más Lago P. Eradication of poliomyelitis in Cuba: a historical perspective. Bull World Health Organ 1999, 77:681-687. 2557718, 10516790.
12. Risi JB. The control of poliomyelitis in Brazil. Rev Infect Dis 1984, 6:S400-S403. 10.1093/clinids/6.Supplement_2.S400, 6740081.
13. Prevots DR, Atti ML CD, Sallabanda A, Diamanti E, Aylward RB, Kakariqqi E, Fiore L, Ylli A, van der Avoort HG, Sutter RW, et al. Outbreak of paralytic poliomyelitis in Albania, 1996: high attack rate among adults and apparent interruption of transmission following nationwide mass vaccination. Clin Infect Dis 1998, 26:419-425. 10.1086/516312, 9502465.
14. Centers for Disease Control and Prevention Outbreaks following wild poliovirus importations --- Europe, Africa, and Asia, January 2009-September 2010. Morb Mortal Wkly Rep 2010, 59:1393-1399. Centers for Disease Control and Prevention.
15. Gregory CJ, Ndiaye S, Patel M, Hakizamana E, Wannemuehler K, Ndinga E, Chu S, Talani P, Kretsinger K. Investigation of elevated case-fatality rate in poliomyelitis outbreak in Pointe Noire, Republic of Congo, 2010. Clin Infect Dis 2012, 55:1299-1306. 10.1093/cid/cis715, 22911644.
16. World Health Organization Outbreak news. Poliomyelitis, Namibia. Wkly Epidemiol Rec 2006, 81:238. World Health Organization.
17. Oostvogel P, van Wijngaarden J, van der Avoort HG, Mulders MN, Conyn-van Spaendonck MA, Rümke H, van Steenis G, van Loon AM. Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992-3. Lancet 1994, 344:665-670. 10.1016/S0140-6736(94)92091-5, 7915354.
18. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet 2007, 369:1363-1371. 10.1016/S0140-6736(07)60532-7, 17448822.
19. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the global polio eradication initiative. Vaccine 2011, 29:334-343.
20. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013, 23:703-749.
21. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Expert review on poliovirus immunity and transmission. Risk Anal 2013, 33:544-605. 10.1111/j.1539-6924.2012.01864.x, 22804479.
22. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, et al. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013, 33:606-646. 10.1111/risa.12031, 23550968.
23. Sterman J. Business dynamics: systems thinking and modeling for a complex world 2001, Boston, MA: McGraw-Hill.
24. Lloyd AL. Realistic distributions of infectious periods in epidemic models: changing patterns of persistence and dynamics. Theor Popul Biol 2001, 60:59-71. 10.1006/tpbi.2001.1525, 11589638.
25. Duintjer Tebbens RJ, Pallansch MA, Kim J-H, Burns CC, Kew OM, Oberste MS, Diop O, Wassilak SGF, Cochi SL, Thompson KM. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013, 23:680-702.
26. World population prospects: the 2010 revision. http://esa.un.org/unpd/wpp/Documentation/WPP%202010%20publications.htm.
27. World population prospects: the 2012 revision. http://esa.un.org/unpd/wpp/index.htm.
28. Centers for Disease Control and Prevention Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011. MMWR Morb Mortal Wkly Rep 2011, 60:846-850. Centers for Disease Control and Prevention.
29. World Health Organization Summary of discussions and recommendations, 16th informal consultation of the global polio laboratory network, 22-23 September 2010, WHO/HQ 2010, Geneva, Switzerland: World Health Organization, World Health Organization.
30. Wassilak SGF, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J Infect Dis 2011, 203:898-909. 10.1093/infdis/jiq140, 3068031, 21402542.
31. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010, 172:1213-1229. 10.1093/aje/kwq320, 2991634, 20978089.
32. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal 2006, 26:1541-1556. 10.1111/j.1539-6924.2006.00843.x, 17184396.
33. Giwa FJ, Olayinka AT, Ogunshola FT. Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria. Vaccine 2012, 30:6759-6765. 10.1016/j.vaccine.2012.09.023, 23000220.
34. Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MAE. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005, 191:990-999. 10.1086/427810, 15717277.
35. Glezen PW, McCollough RH, Lamb GA, Chin TDY. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol 1969, 90:146-156.
36. Glezen WP, Lamb GA, Belden EA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 1966, 83:224-237.
37. Smith JWG, Lee JA, Fletcher WB, Yetts R, Magrath DI, Perkins FT. The response to oral poliovaccine in persons aged 16-18 years. Journal of Hygiene Cambridge 1976, 76:235-247.
38. Siegert R, Enders-Ruckle G, Oehme J, Waller D. Der einfluß der prävakzinalen immunität auf die virusausscheidung und antikörperproduktion nach polio-schluckimpfung mit Typ I (Sabin) [the effect of prevaccinal immunity on virus excretion and antibody production after polio immunization with type I (Sabin)]. Deutsche medizinische Wochenschrift 1963, 88:1586-1594. 10.1055/s-0028-1112269, 14047334.
39. Mayer BT, Eisenberg JN, Henry CJ, Gomes MG, Ionides EL, Koopman JS. Successes and shortcomings of polio eradication: a transmission modeling analysis. Am J Epidemiol 2013, 177:1236-1245. 10.1093/aje/kws378, 23592542.
40. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis 2014, (In press). doi:10.1093/infdis/jit834.
41. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Reviews of Vaccines 2012, 11:449-459.
42. Lowther SA, Roesel S, O'Connor P, Landaverde M, Oblapenko G, Deshevoi S, Ajay G, Buff A, Safwat H, Salla M, et al. World Health Organization regional assessments of the risks of poliovirus outbreaks. Risk Anal 2013, 33:664-679. 10.1111/risa.12032, 23520991.
43. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014, (In press). doi:10.1093/infdis/jit845.
44. Kidd S, Goodson JL, Aramburu J, Morais A, Gaye A, Wannemuehler K, Buffington J, Gerber S, Wassilak S, Uzicanin A. Poliomyelitis outbreaks in Angola genetically linked to India: risk factors and implications for prevention of outbreaks due to wild poliovirus importations. Vaccine 2011, 29:3760-3766. 10.1016/j.vaccine.2011.03.034, 21440639.
45. Centers for Disease C, Prevention Notes from the field: outbreak of poliomyelitis--Somalia and Kenya, May 2013. Morb Mortal Wkly Rep 2013, 62:484. Centers for Disease C, Prevention.